The complex relationships between sentinel node positivity, patient age, and primary tumor desmoplasia: Analysis of 2303 melanoma patients treated at a single center

Annals of Surgical Oncology

Volumn 15, Issue 2, 2008, Pages 630-637

  Sassen, Sander ^a   Shaw, Helen M ^a,b   Colman, Marjorie H ^a   Scolyer, Richard A ^a,b   Thompson, John F ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Desmoplastic histogenetic type; Melanoma; Patient age; Sentinel node biopsy; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PATIENT; FEMALE; HISTOGENESIS; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MITOSIS; MULTIVARIATE ANALYSIS; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SEX; SKIN ULCER; SURVIVAL RATE; TUMOR VOLUME; UNIVARIATE ANALYSIS; AGE; AUSTRALIA; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SKIN TUMOR; SURVIVAL;

ADULT; AGE FACTORS; AGED; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEW SOUTH WALES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 40649125059     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9684-1     Document Type: Article

References (29)

1. McMasters KM, Wong SL, Edwards MJ, et al. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery 2001;130:151-6
2. Wagner JD, Gordon MS, Chuang TY, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 2000;89:453-62
3. Nguyen CL, McClay EF, Cole DJ, et al. Melanoma thickness and histology predict sentinel lymph node status. Am J Surg 2001;181:8-11
4. Porter GA, Ross MI, Berman RS, Lee JE, Mansfield PF, Gershenwald JE. Significance of multiple nodal basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. Ann Surg Oncol 2000;7:256-61
5. Rousseau DL Jr, Ross MI, Johnson MM, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 2003;10:569-74
6. Bedrosian I, Faries MB, Guerry Dt, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol 2000;7:262-7
7. Thompson JF, Shaw HM. Sentinel node metastasis from thin melanomas with vertical growth phase. Ann Surg Oncol 2000;7:251-2
8. Bleicher RJ, Essner R, Foshag LJ, Wanek LA, Morton DL. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 2003;21:1326-31
9. Chao C, Martin RC 2nd, Ross MI, et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol 2004;11:259-64
10. Scolyer RA, Thompson JF, Quinn MJ. Desmoplastic melanoma and sentinel node biopsy. Presented at the Royal Australasian College of Surgeons Annual Scientific Meeting, Perth, Australia, May 2006
11. Carlson GW. Age and the incidence of sentinel lymph node metastases in melanoma. Ann Surg Oncol 2004;11:236-7
12. Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 2007;109:100-8
13. Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 2004;11:247-58
14. Delman KA, Murray DH, Lawson M, et al. Despite a decreased incidence of positive sentinel lymph nodes, advanced age is associated with an increased incidence of distant recurrences in patients with melanoma. Ann Surg Oncol 2006;13(Suppl):63
15. Caraco C, Marone U, Botti G, Celentano E, Lastoria S, Mozzillo N. Age as predictor in patients with cutaneous melanoma submitted to sentinel lymph node biopsy. Eur J Surg Oncol 2006;32:970-3
16. Gyorki DE, Busam K, Panageas K, Brady MS, Coit DG. Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma. Ann Surg Oncol 2003;10:403-7
17. Livestro DP, Muzikansky A, Kaine EM, et al. Biology of desmoplastic melanoma: a case-control comparison with other melanomas. J Clin Oncol 2005;23:6739-46
18. Pawlik TM, Ross MI, Prieto VG, et al. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer 2006;106:900-6
19. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34
20. Uren RF, Hoefnagle CA. Lymphoscintigraphy. In: Thompson JF, Morton DL, Kroon BBR (eds). Textbook of Melanoma. London: Martin Dunitz, 2004; 339-64
21. Thompson JF, Niewind P, Uren RF, Bosch CM, Howman-Giles R, Vrouenraets BC. Single-dose isotope injection for both preoperative lymphoscintigraphy and intraoperative sentinel lymph node identification in melanoma patients. Melanoma Res 1997;7:500-6
22. Li LX, Scolyer RA, Ka VS, et al. Pathologic review of negative sentinel lymph nodes in melanoma patients with regional recurrence: a clinicopathologic study of 1152 patients undergoing sentinel lymph node biopsy. Am J Surg Pathol 2003;27:1197-202
23. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003;97:1488-98
24. McCarthy SW, Scolyer RA, Palmer AA. Desmoplastic melanoma: a diagnostic trap for the unwary. Pathology 2004;36:445-51
25. Busam KJ, Mujumdar U, Hummer AJ, et al. Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors. Am J Surg Pathol 2004;28:1518-25
26. McCarthy SW, Crotty KA, Scolyer RA. Desmoplastic melanoma and desmoplastic neurotropic melanoma. In: LeBoit PE, Burg G, Weedon D, Sarasian A (eds). WHO Classification of Tumours: Pathology and Genetics of Tumours of the Skin. Lyon: IARC Press, 2006;76-8
27. Quinn MJ, Crotty KA, Thompson JF, Coates AS, O'Brien CJ, McCarthy WH. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer 1998;83:1128-35
28. Manganoni AM, Farisoglio C, Farfaglia R, et al. Regression in thin melanomas does not represent a risk factor for sentinel lymph node involvement. Eur J Dermatol 2007;17:95-6
29. Olah J, Gyulai R, Korom I, Varga E, Dobozy A. Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. Br J Dermatol 2003;149:662-3